Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus

Journal of Diabetes and its Complications

Volumn 22, Issue 6, 2008, Pages 384-388

  Awadallah, Samir M ^a   Saleh, Suleiman A ^a   Abu Shaqra, Qasem M ^b   Hilow, Hisham ^c  

^a HASHEMITE UNIVERSITY   (Jordan)

^b Diagnostic Medical Laboratories   (Jordan)

^c UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Cystatin C; Diabetes; Haptoglobin; Microalbuminuria

Indexed keywords

CREATININE; CYSTATIN C; HAPTOGLOBIN;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; FEMALE; HUMAN; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; SERUM; URINE;

AGED; AGING; ALBUMINURIA; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FASTING; FEMALE; HAPTOGLOBINS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHENOTYPE; TIME FACTORS;

EID: 54049117269     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.07.004     Document Type: Article

References (19)

1. Aksun S.A., Ozmen D., Ozmen B., Parildar Z., Mutaf I., Turgan N., Habif S., Kumanliogluc K., and Bayindir O. Beta2-microglobulin and Cystatin C in Type 2 diabetes: Assessment of diabetic nephropathy. Experimental and Clinical Endocrinology & Diabetes 112 (2004) 1195-1200
2. American Diabetes Association. Clinical practice recommendations 2001: Diabetic nephropathy. Diabetes Care 24 Suppl. 1 (2001) S69-S72
3. American Diabetes Association. Diabetic nephropathy (position statement). Diabetes Care 26 Suppl. 1 (2003) S94-S98
4. Asleh R., and Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vascular Health and Risk Management 1 (2005) 19-28
5. Awadallah S., and Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios 101 (2000) 145-150
6. Coll E., Botey A., Alvarez L., et al. Serum Cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. American Journal of Kidney Diseases 36 (2000) 29-34
7. Dharnidharka V.R., Kwon C., and Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. American Journal of Kidney Diseases 40 (2002) 221-226
8. Eknoyan G., Hostetter T., Bakris G.L., Hebert L., Levey A.S., Parving H.H., Steffes M.W., and Toto R. Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and digestive and Kidney diseases (NIDDK). American Journal of Kidney Diseases 42 (2003) 617-622
9. Fliser D., and Ritz E. Serum Cystatin C concentration as a marker of renal dysfunction in the elderly. American Journal of Kidney Diseases 37 (2001) 79-83
10. Grubb A.O. Cystatin C: Properties and use as diagnostic marker. Advances in Clinical Chemistry 35 (2001) 63-99
11. Hamad M., and Awadallah S. Age group-associated variations in the pattern of Hp type distribution in Jordanians. Clinica Chimica Acta 300 (2000) 75-81
12. Khan A.G., Khan N., Ishaq M., Sastry E.P., and Rani T.S.H. Increased frequency of Haptoglobin phenotype Hp 1-1 in diabetic patients with complications. International Journal of Diabetes in Developing Countries 22 (2002) 100-102
13. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry 42 (1996) 1589-1600
14. Moczulski D.K., Rogus J.J., and Krolewski A.S. Comment to: FM Nakhoul et al. (2001) Haptoglobin phenotype and diabetes. Diabetologia, 44:602-604. Diabetologia 44 (2001) 2237-2239
15. Mohan V., Meera R., Premalatha G., Deepa R., Miranda P., and Rema M. Frequency of proteinuria in Type 2 diabetes mellitus seen at a diabetes centre in south India. Postgraduate Medical Journal 76 (2000) 569-573
16. Mussap M., Dalla Vestra M., Fioretto P., Saller A., Varagnolo M., Nosadini R., and Plebani M. Cystatin C is a more sensitive marker than creatinine for estimation of GFR in Type 2 diabetic patients. Kidney International 61 (2002) 1453-1461
17. Nakhoul F.M., Zoabi R., Kanter Y., Zoabi M., Skorecki K., Hochberg I., Leibu R., Miller B., and Levy A.P. Haptoglobin phenotypes and diabetic nephropathy. Diabetologia 44 (2001) 602-604
18. Tseng C.F., Lin C.C., Huang H.Y., Liu H.C., and Mao S.J. Antioxidant role of human haptoglobin. Proteomics 4 (2004) 2221-2228
19. Wasen E., Isoaho R., Mattila K., Vahlberg T., Kivela S.L., and Irjala K. Renal impairment associated with diabetes in the elderly. Diabetes Care 27 (2004) 2648-2653